PSIL 020
Alternative Names: PSIL-020Latest Information Update: 17 May 2024
At a glance
- Originator Psilera
- Class Antidementias; Neuropsychotherapeutics; Small molecules
- Mechanism of Action Serotonin 6 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 02 May 2024 Psilera has patent protection for PSIL 020 (Psilera pipeline May 2024)
- 02 May 2024 Preclinical trials in Unspecified in USA (unspecified route) prior to May 2024 (Psilera pipeline May 2024)